gene sequencing on 1018 patients with CLL (558 followed from diagnosis and 460 entered into the UK CLL4 trial).
INTRODUCTION
In 1999, two studies showed that patients with chronic lymphocytic leukemia (CLL) whose immunoglobulin variable region genes (IGHV) had undergone somatic hypermutation (SHM) leading to <98% identity to the germline sequence (M-CLL) had a significantly better overall survival than patients with 'unmutated' IGHV genes (U-CLL) (Damle et al, 1999; Hamblin et al, 1999) . Many subsequent retrospective and prospective studies have confirmed this observation and shown that IGHV gene mutational status using a 98% cut-off also predicts disease progression, time to first treatment and progression free survival. However, the mathematical cut-off which correlates best with clinical outcome still remains controversial;
we and others have previously shown that cut-off's using 97% or 95% identity to the germline sequence have clinical relevance and that cases with 97% identity may have an intermediate outcome compared to those with <97% or >97% identity (Hamblin et al, 2008; Krober et al, 2002; Oscier et al, 2010; Tobin et al, 2005) .
The 98% cut-off was originally chosen to avoid scoring polymorphic variants as mutations. However, 98% and 99% identity are frequently the consequence of SHM rather than polymorphisms (Davis et al, 2003) and even single base changes can affect the binding specificity of the B-cell receptor (BcR) (Barbas et al, 1995; Murray et al, 2008) . In addition, methodological factors such as the choice of PCR primers and immunoglobulin database may affect calculation of percentage identity to germline and classification of a case as mutated or unmutated. Accordingly, International guidelines recommend caution in assigning mutational status and predicted outcome in cases with 'borderline' IGHV identity (Ghia et al, 2007) .
It has also become increasingly clear that other features of the immunoglobulin gene sequence, in addition to mutational load, can influence prognosis. In 2002, it was observed that usage of the IGHV3-21 gene was an independent unfavourable prognostic marker irrespective of IGHV gene mutational status (Tobin et al, 2002) . The same group then demonstrated that a subset of CLL cases utilising IGHV3-21 had a very short, highly similar, if not identical, heavy complementarity-determining region 3 (VH CDR3) and showed biased utilisation of the IGLV3-21 gene (Tobin et al, 2003) . In 2004 the term 'stereotyped' BcR was introduced that now describes the approximately 30% of CLL cases with similar VH CDR3 amino acid sequences (Messmer et al, 2004; Darzentas et al, 2010 (Stamatopoulos et al, 2007; Bomben et al, 2009; Marincevic et al, 2010; Rossi et al, 2009; Sutton et al, 2009; Chu et al, 2010; Kanduri et al, 2012; Ntoufa et al, 2012; Strefford et al, 2013; Baliakis et al, 2014 Baliakis et al, , 2015 .
We have further addressed the clinical significance of borderline IGHV identity in 1018 CLL patients comprising a diagnostic cohort with predominantly Binet stage A disease and a second cohort entered into the UKCLL4 trial. The outcome of patients with 97% identity was comparable to those with 98% identity in both cohorts and distinct from other cases currently classified as having M-CLL.
MATERIALS AND METHODS

Patients
Blood samples were obtained with patient consent at or close to diagnosis from 350 patients diagnosed at the Royal Bournemouth Hospital (Cohort 1) and 208 patients diagnosed in Siena (Cohort 2), and at trial entry from 460 patients entered into the UK LRF CLL4 trial. The diagnosis of CLL was based on the revised International Workshop Chronic Lymphocytic Leukemia/National Cancer Institute (IWCLL/NCI) guidelines for cases from cohorts 1 and 2 and the 1996 NCI guidelines for patients entered into the UK CLL4 trial. The study was approved by the local ethics committee of the participating institutions.
Analysis of IGHV-IGHD-IGHJ gene rearrangements
IGHV-IGHD-IGHJ gene rearrangements were sequenced as previously described (Hamblin et al, 2008) . All sequences were aligned to the IMGT/V-QUEST database prior to the recent updated version 3.3.0 (20 February 2014) and considered mutated if their percentage identity to germline was <98%. As the identification of new IGHV genes and new alleles (Xochelli et al, 2015) will influence the precise determination of SHM status, all of cohort 1 and CLL4 cases identified as having 96-98.99% identity to the germline sequence were re-aligned to the updated IMGT/V-QUEST programme version: 3.3.0 (20 February 2014) -IMGT/V-QUEST reference directory release: 201414-4 (3 April 2014). Reanalysis of these cases was chosen as any changes observed in these patients would potentially affect which mutational subgroup they would be assigned to.
All cases were assessed for stereotypy by comparing IGHV gene usage, CDR3 sequence and CDR3 length with the published sequences of the 19 "major" stereotypic subsets (Agathangelidis et al, 2012) and assigned to one of these subsets if these criteria were met. 
Other Prognostic Biomarkers
Flow cytometric testing for ZAP-70 and CD38 expression, cytogenetic analysis, FISH for del(13q), del(11q), del(17p) and trisomy 12 and NOTCH1 and SF3B1 mutation screening were performed as previously described (Oscier et al, 2002; Orchard et al, 2004; Oscier et al, 2013) .
Statistical Analysis
Comparative and statistical analysis was performed using IBM SPSS Statistics 21 Data
Mining and Statistical Analysis Software (IBM Corp. Armonk, NY USA). For patients in cohorts 1 and 2, time to first treatment (TTFT) and overall survival (OS) were calculated from date of diagnosis to date of first treatment or death respectively and censored if these were not reached.
For patients entered into the UK CLL4 trial PFS was expressed as time from randomization to relapse needing further therapy, progression, or death from any cause, and OS was calculated from trial entry to death from any cause. Curves were generated using the method of Kaplan and Meier. The relationship between known prognostic markers and TTFT, PFS and OS was assessed and p-values were generated using the SPSS software.
RESULTS
Clinical and Laboratory Features and Cohort Comparison
Clinical and laboratory findings for the three cohorts are summarised in Table I . Significant differences between the cohorts are indicated with an asterisk. The median follow-up was 7.31 years (range 0-35 years). 687 patients were followed up for >5 years and 304 for >10 years. In both cohorts 1 and 2, 90% of patients requiring treatment were treated initially and at relapse with an alkylating agent and / or purine analogue, according to guidelines that were current at the time of treatment. Patients entered into the UK CLL4 trial were randomised to receive either chlorambucil or fludarabine alone or in combination with cyclophosphamide (Catovsky et al, 2007) . Cytogenetic and FISH analysis were carried out prior to treatment in 79% of cohort 1 cases and 46% were tested within 2 years of diagnosis. In cohort 2 analyses were carried out at diagnosis or prior to treatment and for the CLL4 cohort, analysis was carried out at trial entry (pre-treatment), with 67% being within 2 years of diagnosis.
As no significant differences were observed between cohorts 1 and 2 for any of the observations summarised in Table I cut-off that provided the best predictor of outcome, analysis was initially performed on the stage A cohort using TTFT as an endpoint to obviate the effect of varying treatment regimens. We carried out Cox regression analysis to determine hazard ratios (HR) for each mutational interval differing by 1% from 95% -100% identities, comparing the TTFT. When compared to cases with <95% identity (median TTFT of 273 month), a significant difference in TTFT first occurred at 97% with a median TTFT of 102 and a HR of 2.2, whereas, the median TTFT and HRs for 98%, 99% and 100% were 44, 48 and 55 months and 3.7, 4.4 and 4.8 respectively (Table II ). This analysis suggested that stage A cases could be divided into three subgroups with differing median TTFT's based on their mutational status; those with <97% identity having a low risk of a short TTFT (HR 0-1.6) , those with 97% identity having an intermediate risk (HR 2.2) -and those with ≥98% identity having a high risk ).
Influence of BCR Stereotypy
Next, we wished to determine whether the different outcome for Stage A patients with 97% identity was a consequence of a differing incidence of major stereotypes, especially stereotypic subset #2, which is well documented (Baliakas et al, 2015) and confirmed here (Fig S1) to be associated with poor outcome independent of IGHV mutational status and is enriched with cases with a low mutational load.
Within the stage A cohort, 42/460 (9.1%) cases were assigned to one of 14 of the 19 'major' stereotypic subsets (Agathangelidis et al, 2012) with the following distribution: low risk subgroup -4.5%, intermediate -3% and high risk subgroup -18.2%. Subsets #1 and #2 were the most frequently observed stereotypic subsets among the stage A cohort, both accounting for 21% (9/42) each of all stereotypic cases.
Cox regression analysis for each mutational interval (95-100%) was initially repeated excluding all major stereotype cases, and now the HR and the median TTFT for cases with 97% and 98% were very similar; with a median TTFT of 102 and 105 months and HRs of 2.3 and 2.6 respectively (Table III) . Secondly, because 4/5 stereotypic cases with 97% or 98% identity belonged to subset #2, analysis was repeated with the exclusion of this subset only. The HR and TTFT's of the 97% and 98% identity cases remained very similar or the same (HRs 2.2 and 2.9, TTFT 102 and 105 months respectively) as the previous analysis when all major stereotypes were excluded, indicating that the effect of stereotypy on TTFT was a consequence of subset #2.
Exclusion of subset #2 enabled the remaining cases to be divided into 3 risk groups: 1) low risk We then carried out proportional hazard analysis without subset #2 cases, comparing the standard cut-off (98%) to either a model with 97% as the cut-off or the 3 mutational subgroup model (<97%, 97-98.99% and ≥99%). We found no difference in the models using either 98% or 97% as a cut-off (p=0.338) but the 3 subgroup model showed a significant improvement at predicting TTFT than both of these models (p=0.005 and p=0.003 respectively).
Kaplan Meier survival curves and the median TTFT for stage A cases were then determined for the 3 subgroup model without subset #2. Of note there was a significant difference in TTFT between <97% and 97-98.99% (median TTFT not reached and 105 months respectively; p<0.001) and between 97-98.99% and ≥99% (105 and 52 months; p=0.002) (Fig 1A) .
When this model was applied to cohorts 1 and 2, including those with Binet stage B and C disease, to assess OS, a significant difference was observed between each of the three subgroups; with a median OS of 231, 141 and 111 months respectively (p=0.003 and p=0.005) (Fig 1B) .
UK CLL4 cohort
Within the CLL4 cohort 96/460 (20.9%) cases were assigned to 18/19 major stereotypic subsets; subset #2 constituted 36.5% (35/82) of all stereotypic cases and 25/35 had an intermediate identity of 97% or 98%. In light of this, subset #2 cases were once again excluded from analysis when the three subgroup model was assessed in the CLL4 cohort.
Initially, proportional hazard model analysis was repeated in the CLL4 cohort using PFS as the predictor of outcome. Again a significant improvement in predicting outcome was observed when using the three mutational subgroups over the current 98% cut-off (p=0.003), regardless of whether treatment arm was included in the analysis (p<0.001).
Kaplan Meier survival curves and median survival times were then determined using the 3 mutational subgroups. A significant difference was noted between PFS of cases with <97% identity and those with 97-98.99%, (median PFS 42 and 30 months respectively; p<0.001) however, significance was not reached between those with 97-98.99% and those with ≥99% (median PFS 20; p=0.124) (Fig 1C) . Similarly, a significant difference in OS was observed between cases with <97% identity and those with 97-98.99% (p<0.001), with a median OS of 121 months and 62 months respectively, but not between those with 97-98.99% and ≥99% (median OS 61 months; p=0.323) (Fig 1D) 
Multivariate survival analyses
Multivariate survival analyses were then performed in models that included the following parameters: age at diagnosis, gender, CD38 and ZAP 70 positivity, del(13q), trisomy 12, del(11q), del(17p), NOTCH1 and SF3B1 mutation and treatment arm. Tables SI and SII highlight which biomarkers were significant in univariate analysis for either TTFT in the stage A cohort, PFS in and also as an independent marker of OS together with age at diagnosis, CD38 expression and del(17p) in all cases from cohorts 1 and 2 (Table IV) . The analyses were then repeated using the intermediate subgroup (97-98.99% identity) as the reference category to confirm the independent significance of each mutational subgroup, and all the above factors remained significant independent predictors of TTFT and OS respectively (Table SIII) .
Multivariate survival analyses of the CLL4 cohort showed that the three mutational subgroup model was an independent predictor of PFS, together with del(11q), del(17p) and treatment type, and of OS, together with age, gender, CD38, del(11q) and del(17p) ( Table V) . When analyses was repeated using the intermediate subgroup (97-98.99% identity) as the reference category, significance was lost for the high risk subgroup (≥99% identity) for both PFS and OS (Table SIV) .
Investigation of other factors that might account for the intermediate outcome of cases with
97.0 to 98.99% identity
Methodological factors
We initially sought to exclude the possibility that the intermediate TTFT of cases with 97-98.99% identity reflected the calculation of IGHV gene mutational load when different PCR primers were used for analysis. Seventy percent of cohorts 1 and 2 were amplified with leader primer and TTFT and OS analysis of the three mutational subgroups based on, only those cases amplified using the leader primer did not change the statistically significant differences between the three subgroups.
In addition, as a result of the recent update to the IMGT/V-QUEST reference directory, available sequences with borderline identities across the subgroups (152/204 96-98.99%) were reanalysed using IMGT/V-QUEST v.3.3.0 reference directory release: 201414-4 (3 April 2014) which includes all newly identified IGHV genes and alleles. Only 1/152 sequences from a patient with Binet stage C disease in the combined cohorts 1 and 2 changed from 98% to 99% identity.
Analysis of OS in cohorts 1 and 2 was repeated with no significant changes observed; these reanalysed results are shown in Figure 1B .
Finally, the frequency of polymorphisms was assessed in 6 cases with 97% identity utilising IGHV3-23 by comparing the CLL IGHV gene sequence with its corresponding germline sequence.
All genomic variations classified as mutations based on the CLL sequence were confirmed as mutations. 
SF3B1 and NOTCH1 mutations
As SF3B1 and NOTCH1 mutations have adverse prognostic significance in CLL and their incidence differs between M-CLL and U-CLL and among stereotypic subsets, we compared the incidence of these mutations among the 3 mutational risk groups (Strefford et al, 2013; Oscier et al, 2013; Rossi et al, 2011) . SF3B1 and NOTCH1 mutation status was available for 315 CLL4 cases and for 159 cohort 1 cases (excluding subset #2 cases). Of note the incidence of SF3B1 mutated cases was significantly higher in the intermediate subgroup than the low risk group (27% and 5% respectively; p=<0.001) and there was also a trend towards a higher incidence in the intermediate group than in the high risk group (15%; p=0.0564). The incidence of NOTCH1 mutated cases was significantly less in the low risk subgroup than in the high risk subgroup (1% and 13% respectively; p<0.001) but the incidence in the intermediate subgroup (6%) was not significantly different from either of the other subgroups.
There were too few cases in each of the subgroups to carry out survival analysis in the stage A cohort, but as highlighted earlier SF3B1 and NOTCH1 did not show independent significance in multivariate analysis in the CLL4 cohort. In the UK CLL4 trial cohort, again excluding stereotyped subset #2, cases with 97-98.99% identity had a significantly shorter PFS and OS than those with <97% identity but there was no difference between the 97-98.99% and ≥99% groups. Multivariate analyses showed that the 3 mutational group model was an independent predictor of PFS and OS only when <97% identity cases (but not 97-98.99% identity cases) were used as the reference category.
U-CLL and M-CLL, defined by using 98% identity as a cut-off, are widely considered to arise from two distinct subsets of normal B cells at different stages of differentiation. The differing consequences of engagement of the BcR by antigen within the CLL microenvironment (Stevenson et al, 2011; Packham et al, 2014) in these subsets exerts a strong influence on clinical outcome. Although it is well recognised that there is both biological and clinical heterogeneity within the 2 mutational subsets, especially M-CLL (Oscier et al, 2010; Pflug et al, 2014; Rassenti et al, 2008; Bulian et al 2014; Pepper et al, 2015; Rossi et al, 2009; Paterson et al, 2012) , one implication of this two-subset model is that cases with 97% identity might be expected to show greater clinical similarity to cases with higher mutational loads than to cases with 98% identity.
Data from our cohorts strongly suggest that the outcome of patients with 97% identity is more similar to those with 98% identity than to those with greater IGHV mutational loads. We could identify neither methodological nor biological factors to account for the poorer outcome of cases with 97% identity compared to those with <97% identity, although the higher incidence of SF3B1 mutations in the intermediate risk group, even without stereotypic subset #2 cases, is of interest and requires confirmation in a larger cohort.
Recently an epigenetic signature based on the methylation status of 5 CpG sites has been identified which reliably classified CLL cases into 3 clusters with differing clinical outcomes. The authors postulated that the intermediate methylation cluster, which is enriched with cases having a low IGHV mutational load, might reflect CLL cases derived from an antigen-experienced, germinal centre-independent marginal zone B cell (Queirós et al, 2015) . A recent, subsequent study integrated this epigenetic data with genomic data and noted higher frequencies of SF3B1
and MYD88 mutations, biased usage of IGVH3-21 and IGHV1-18 genes and of stereotypic subset #2 in the intermediate methylation cluster (Puente et al, 2015) .
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